Baseline characteristics of the study participants
| Control participants N=87 | HIV-positive participants N=73 | p Value | |
|---|---|---|---|
| Age | 57±8 | 55±8 | 0.15 |
| Male (N) | 87 | 73 | |
| Smoking n (%) | 21 (24) | 22 (30) | 0.36 |
| Diabetes n (%) | 24 (28) | 9 (13) | 0.02 |
| Triglycerides (mmol/L) | 1.8±1.5 | 2.5±1.7 | 0.04 |
| Total cholesterol (mmol/L) | 4.7±1.3 | 5±1.3 | 0.14 |
| LDL cholesterol (mmol/L) | 2.6±1.5 | 2.9±1 | 0.36 |
| HDL cholesterol (mmol/L) | 1.3±0.3 | 1.1±0.3 | 0.22 |
| BMI (kg/m2) | 29.0±7.4 | 24.8±4.3 | <0.001 |
| STEMI n (%) | 13 (15) | 8 (11) | 0.48 |
| NSTEMI n (%) | 41 (47) | 30 (41) | 0.48 |
| High-risk chest pain n (%) | 33 (38) | 35 (48) | 0.20 |
| Hypertension treatment n (%) | 30 (35) | 46 (63) | <0.001 |
| Statin usage n (%) | 29 (33) | 47 (64) | <0.001 |
| Duration of HIV diagnosis (years) | NA | 11.02±4 | NA |
| Viral load <50 (%) | NA | 89 | NA |
| CD4 count | NA | 510±220 | NA |
| CRP (mg/L)* | 3.7±3.6 | 13.4±15.4 | <0.001 |
| PI n (%) | NA | (51) 70 | NA |
| NRTI n (%) | NA | (62) 85 | NA |
| NNRTI n (%) | NA | (68) 82 | NA |
| Abacavir usage n (%)† | NA | 21 (29) | NA |
Continuous data are mean±SD unless otherwise indicated.
*As measured on the day of admission.
†As documented as part of ART regime on the day of admission.
BMI, body mass index; CRP, C reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NA, not available; NNRTI, non-nucleoside reverse transcription inhibitor; NRTI, nucleoside reverse transcription inhibitor; NSTEMI, non-ST elevation myocardial infarction; PI, protease inhibitor; STEMI, ST elevation myocardial infarction; UAP, unstable angina pectoris.